Satsuma Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 70.06 million compared to USD 51.17 million a year ago. Basic loss per share from continuing operations was USD 2.19 compared to USD 1.75 a year ago.
Satsuma Pharmaceuticals, Inc.
Equities
STSA
US80405P1075
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
-3.46% | 102B | |
+1.41% | 96.29B | |
+2.13% | 22.18B | |
-15.84% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.65% | 16.36B | |
+4.39% | 13.97B | |
+31.35% | 12.17B |